Toulouse University Hospital
Clinical Trials
748
Trial Phases
6 Phases
Drug Approvals
0
Drug Approvals
No drug approvals found
This company may not have drug approvals in our database
Clinical Trials
Distribution across different clinical trial phases (529 trials with phase data)• Click on a phase to view related trials
Exploration of the Variability of Exposure to Antiretroviral Treatment in Hair With a View to Validating Its Value as a Diagnostic Tool for Partial and/or Total Non-compliance With Treatment
- Conditions
- HIV (Human Immunodeficiency Virus)
- First Posted Date
- 2025-07-14
- Last Posted Date
- 2025-07-14
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 30
- Registration Number
- NCT07062614
- Locations
- 🇫🇷
Infectious and Tropical Diseases Department, Purpan University Hospital, Toulouse Place du Docteur Baylac, Toulouse, France
Use of a New Diagnostic Tool in the Detection and Characterization of Endometriosis Lesions
- Conditions
- Endometriosis
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 20
- Registration Number
- NCT07053982
- Locations
- 🇫🇷
Toulouse, Rangueil Hospital, Toulouse, France
Cognitive Remediation Method Using Rhythmic, Vocal and Corporal Musical Learning for Schizophrenia
- Conditions
- Schizophrenia Disorders
- First Posted Date
- 2025-07-08
- Last Posted Date
- 2025-07-08
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 120
- Registration Number
- NCT07055204
- Locations
- 🇫🇷
CH de la Côte Basque, Bayonne, France
🇫🇷CH Le Vinatier, Bron, France
🇫🇷Assistance Publique Hôpitaux de Marseille, Marseille, France
ICOPE INTENSE-K Pilot Study
- Conditions
- Ageing
- First Posted Date
- 2025-07-03
- Last Posted Date
- 2025-07-03
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 40
- Registration Number
- NCT07048860
- Locations
- 🇫🇷
Cité de la santé - Hopital La Grave, Toulouse, France
Pilot Study to Establish a Repertoire of Megakaryocyte Markers, Quantifiable by Spectral Flow Cytometry, in Bone Marrow and Circulating in Patients Undergoing Cardiac Surgery for Bypass Grafting
- Conditions
- Cardiac Surgery for Bypass Grafting
- Interventions
- Biological: Blood and bone marrow sampling
- First Posted Date
- 2025-06-18
- Last Posted Date
- 2025-06-18
- Lead Sponsor
- University Hospital, Toulouse
- Target Recruit Count
- 20
- Registration Number
- NCT07026851
- Locations
- 🇫🇷
Toulouse University Hospital, Toulouse, France
- Prev
- 1
- 2
- 3
- 4
- 5
- 150
- Next
News
Lixisenatide Shows Promise in Slowing Parkinson's Disease Progression in Phase 2 Trial
A Phase 2 trial of Sanofi's lixisenatide demonstrated the GLP-1 agonist's potential to halt motor symptom progression in Parkinson's disease patients over 12 months.